Navigation Links
Enigma Diagnostics Showcases Its Unique Fully Automated rtPCR Based ML (Mini-Laboratory) Instrument For Point-of-Care Testing at MEDICA 2009 In Dusseldorf, Germany
Date:11/18/2009

PORTON DOWN, England, Nov. 18 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised point-of-care molecular diagnostics company, announces the showcasing of its fully automated Point-of-Care mini-laboratory instrument, the Enigma ML, at MEDICA 2009 at the Dusseldorf Trade Fair Centrehas in Dusseldorf, Germany in Hall 1, stand E07a between 18-20 November.

The Enigma ML offers "Gold Standard" central reference laboratory standards of testing in an instrument developed for decentralised locations. The ML integrates a range of proprietary miniaturised technologies, including the rapid real-time PCR thermocycler and fully automated sample preparation capability, offering the only instrument platform which can deliver true raw sample to result capability in minutes in any location.

Enigma's miniaturised technology provides the paradigm shift necessary to deliver fast, accurate, low cost multi-sample instrument systems for any clinical or applied market testing at point-of-need. The ML is ideally suited for point-of-care and clinical laboratories including hospital clinics and operating rooms doctors' surgeries and pharmacies with extensive test and treat opportunities.

The affordability and ease of use of the ML instrument offers new and first time testing sites to both developed and emerging healthcare economies using previously unavailable PCR-based detection. The ML will be commercially launched in early Q3 2010 for influenza testing following clinical trials and EU/USA regulatory approvals. Further tests will follow in 2010 and 2011.

"The launch of the Enigma ML will provide a paradigm shift in decentralised healthcare testing. We are excited to showcase the Enigma ML at MEDICA which will offer first time use of real-time PCR and next-generation molecular technologies to an array of global users, said Chairman and CEO John McKinley. "By offering laboratory-standard results in a miniaturised, easy-to-use and cost effective system, we will establish Enigma as the leader of this new global decentralised testing market."

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK-based company specializing in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

In July 2009, Enigma Diagnostics announced that it signed worldwide licensing and supply agreements with GlaxoSmithKline (GSK). Under the agreements, Enigma will develop the first companion diagnostic influenza tests to identify pandemic & resistant strains of the virus for use on the Enigma ML system.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licences from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com

    Contacts

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Tiberend Strategic Advisors, Inc.
    212-827-0020
    Tamara Bright
    tbright@tiberendstrategicadvisors.com
    Chiara DePaolo
    cdepaolo@tiberendstrategicadvisors.com

SOURCE Enigma Diagnostics Limited


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 2009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
2. Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes
3. Ionian Technologies, Inc. Signs Molecular Diagnostic Manufacturing Agreement With Roche Diagnostics
4. Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes
5. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
6. Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
7. Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference
8. FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics Focus Diagnostics
9. Prometheus Launches ProOnc Dx Cancer Diagnostics
10. Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
11. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
Breaking Medicine News(10 mins):